MI reported in August that the cost of the scoping inquiry, which was established in May, was estimated to be €200,000 before the decision to extend the timeline of the inquiry was made.
The final figure is inclusive of VAT.
Also, this newspaper recently revealed that the consultancy firm Crowe and the PR firm Q4PR were due to receive €144,000 and €12,500 respectively for work invoiced until the end of July.
For his part in leading the inquiry, Dr Gabriel Scally was to receive €55,000 for work invoiced until the end of July.
When Dr Scally was appointed on 8 May to lead the scoping inquiry, it was planned that his work would be completed at the end of July.
However, a decision to extend the timeline of the inquiry was made and the final report was published on 12 September.
Recently, the implementation plan for Dr Scally’s recommendations was published.
Additional funding was provided for the screening service in Budget 2019 to address the implementation of the recommendations.
This funding will support implementation of those actions that require additional posts or other investment in 2019.
In addition, the funding provided for 2019 provides for the planned switch to the HPV test as the primary screening test. Funding in 2019 is also provided for the extension of the HPV vaccine to boys